Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial
Glenda Gray(South African Medical Research Council), Mookho Malahleha(University of Cape Town), Michal Juraska(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Asa Tapley(University of Washington), Nigel Garrett(Centre for the AIDS Programme of Research in South Africa), Mina C. Hosseinipour, Janine van Duijn(Janssen (Netherlands)), Caroline Borremans(Janssen (Belgium)), Hanneke Schuitemaker(University of Maryland, Baltimore), Thozama Dubula(Nelson Mandela Academic Hospital), Alex Luedtke(University of Washington), Ludo Lavreys(Janssen (Belgium)), Susan Buchbinder(San Francisco Department of Public Health), James G. Kublin(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Craig Innes(Aurum Institute), Georgia D. Tomaras(Duke University), László Imre, Linda‐Gail Bekker(Desmond Tutu HIV Foundation), Edith Swann(National Institutes of Health), Sheena Kotze, Zaheer Hoosain, Dan H. Barouch(Beth Israel Deaconess Medical Center), Alison Ayres, Fatima Laher(Norwegian Womens Public Health Association), Jessica Andriesen(Adaptive Biotechnologies (United States)), Lawrence Corey(Emory University Hospital), William Brumskine(Aurum Institute), Jackline Odhiambo(Research ICT Africa), Maria Grazia Pau, Daniel J Stieh(Janssen (Netherlands)), Kathryn Mngadi(Aurum Institute), William Kilembe, Erica Lazarus(Norwegian Womens Public Health Association), Philipp Mann(Fred Hutch Cancer Center), Roma Chilengi(National Institute of Public Administration), Huub C. Gelderblom, M. Juliana McElrath(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Peter B. Gilbert(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Steven Nijs(Janssen (Netherlands)), Ollivier Hyrien(Fred Hutch Cancer Center), Julia Hütter(National Institutes of Health), Jon J. Allagappen, Katherine Gill, Philippus Kotze, Wouter Willems(Janssen (Belgium)), John Hural(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Frank Tomaka(Janssen (United States)), Azwidihwi Takalani(Research ICT Africa), Johan Van Hoof(University of Maryland, Baltimore), Mubiana Inambao(University of Namur)
Cited by 40
Related Papers
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the <i>CKR5</i> Structural Gene
|Science|1996|2.5k
Gender-based violence, relationship power, and risk of HIV infection in women attending antenatal clinics in South Africa
|The Lancet|2004|1.3k
Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection
|New England Journal of Medicine|1990|1.3k
DNA vaccine protection against SARS-CoV-2 in rhesus macaques
|Science|2020|1.1k